Xarelto on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2018
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms XaMINA
- Sponsors Bayer
- 23 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2018 Planned End Date changed from 31 Dec 2019 to 31 Oct 2019.
- 24 Sep 2018 Planned primary completion date changed from 30 Sep 2019 to 31 Jul 2019.